Vividion Therapeutics to Bolster its Genomic Abilities Through the Acquisition of Tavros Therapeutics
Shots:
- Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed
- The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology & immunology
- The acquisition was preceded by a 2yrs. strategic collaboration for the development of precision therapeutics targeting cancer-causing proteins
Ref: Bayer | Image: Tavros Therapeutics
Related News:- Vividion Therapeutics Commences P-I Study of VVD-130850 for Advanced Solid and Hematologic Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
